Management Team

Driven • Experienced • Focused • Reliable

 

Bruce Kovacs, MD
Chief Executive Officer

Dr. Kovacs is a co-founder of PharmetRx and inventor of a key molecular genetic technology and other biometrics that are integrated into the PharmetRx technology platform. Bruce was Clinical Professor and Director of the Molecular & Cytogenetics Laboratory at the Keck School of Medicine at USC for over 20 years. He developed several technologies for analysis of DNA/RNA for the purposes of disease diagnosis, drug discovery, and human identification. He has served as a consultant to the U.S. Department of Justice, FBI, and other government agencies in the areas of molecular diagnostics and forensic identification. Dr. Kovacs received his M.D. from the Keck School of Medicine at the University of Southern California.

Hal Lieberman, MHA
Chief Operating Officer

Mr. Lieberman has more than thirty years of experience in healthcare management, including medical devices, pharmaceuticals and health care services. Hal is the former CEO of HemaCare Corporation. His other management experience includes the development of an immune therapy for AIDS, and partnerships with Squibb, Novartis and GlaxoSmithKline. He has served on the board of directors of Atopix Pharmaceuticals, BioDiscovery, Inc., ALine, Inc., and the Pacific Heart, Lung, and Blood Institute. Mr. Lieberman earned a master's degree in healthcare administration from The George Washington University, and is a member of the American College of Healthcare Executives.

Peter Blaisdell, PhD
VP, Clinical Development

Dr. Blaisdell leads clinical development for client drug programs at PharmetRx. In his previous role, he was the Executive Director of Global Study Management at Amgen. He joined Amgen in 1998 supporting clinical research programs in infectious disease and nephrology and supporting the design and conduct of global cardiovascular and nephrology outcomes trials, successfully executing international phase 2 and 3 trials in support of filings, as well as phase 4 trials providing post-marketing support for a variety of therapies. He holds a Ph.D. in Biochemistry from the University of Minnesota, and a BS from the University of Michigan.